These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22542726)

  • 1. Clinical manifestations of human immunodeficiency virus-induced uveitis.
    Kunavisarut P; Sirirungsi W; Pathanapitoon K; Rothova A
    Ophthalmology; 2012 Jul; 119(7):1455-9. PubMed ID: 22542726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
    Rothova A; Schneider M; de Groot-Mijnes JD
    Ophthalmology; 2008 Nov; 115(11):2062-4. PubMed ID: 18562005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular and plasma HIV-1 RNA loads and HIV uveitis.
    Pathanapitoon K; Riemens A; Kongyai N; Sirirungsi W; Leechanachai P; Ausayakhun S; Kalinina Ayuso V; Kunavisarut P; de Groot-Mijnes JD; Rothova A
    AIDS; 2011 Jan; 25(1):81-6. PubMed ID: 21099669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rubella virus- and herpes virus-associated anterior uveitis: clinical manifestations and visual prognosis.
    Wensing B; Relvas LM; Caspers LE; Valentincic NV; Stunf S; de Groot-Mijnes JD; Rothova A
    Ophthalmology; 2011 Oct; 118(10):1905-10. PubMed ID: 21764137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical manifestations of cytomegalovirus-associated posterior uveitis and panuveitis in patients without human immunodeficiency virus infection.
    Pathanapitoon K; Tesavibul N; Choopong P; Boonsopon S; Kongyai N; Ausayakhun S; Kunavisarut P; Rothova A
    JAMA Ophthalmol; 2013 May; 131(5):638-45. PubMed ID: 23494002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.
    Sterling TR; Vlahov D; Astemborski J; Hoover DR; Margolick JB; Quinn TC
    N Engl J Med; 2001 Mar; 344(10):720-5. PubMed ID: 11236775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
    Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
    J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
    Celum CL; Buchbinder SP; Donnell D; Douglas JM; Mayer K; Koblin B; Marmor M; Bozeman S; Grant RM; Flores J; Sheppard HW
    J Infect Dis; 2001 Jan; 183(1):23-35. PubMed ID: 11106536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between HIV disease history and blood HIV-1 DNA load in perinatally infected adolescents and young adults: the ANRS-EP38-IMMIP study.
    Avettand-Fenoel V; Blanche S; Le Chenadec J; Scott-Algara D; Dollfus C; Viard JP; Bouallag N; Benmebarek Y; Rivière Y; Warszawski J; Rouzioux C; Buseyne F
    J Infect Dis; 2012 May; 205(10):1520-8. PubMed ID: 22427678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients.
    Petrara MR; Cattelan AM; Zanchetta M; Sasset L; Freguja R; Gianesin K; Cecchetto MG; Carmona F; De Rossi A
    J Clin Virol; 2012 Mar; 53(3):195-200. PubMed ID: 22209290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
    Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
    Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic manifestations of HIV infections in India in the era of HAART: analysis of 100 consecutive patients evaluated at a tertiary eye care center in India.
    Gharai S; Venkatesh P; Garg S; Sharma SK; Vohra R
    Ophthalmic Epidemiol; 2008; 15(4):264-71. PubMed ID: 18780260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.